Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04830397 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).
A Phase 2 study of Ocular Hypertension and Primary Open Angle Glaucoma, sponsored by Qlaris Bio.
- Completed
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
- 1
- Study location
NCT04830397: Completed Phase 2 study of Ocular Hypertension and Primary Open Angle Glaucoma, sponsored by Qlaris Bio.
NCT04830397 is a Phase 2 study of Ocular Hypertension and Primary Open Angle Glaucoma that has completed, run by Qlaris Bio. The registered enrollment target is 84 participants, below the 277-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04830397, a Phase 2 study of Ocular Hypertension and Primary Open Angle Glaucoma, has completed, sponsored by Qlaris Bio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
- 1
- Study location
Study Summary
Evaluating the safety and tolerability of QLS-101 versus timolol maleate ophthalmic solution in glaucoma or ocular hypertension.
Primary Outcome
Number of participants with treatment-related adverse events will be monitored
Conditions Studied
Interventions
- DRUG Timolol Maleate
- DRUG QLS-101
Study Locations (1)
Georgia
- Dixon Eye Care - Albany
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2021-03-31 |
| Est. Completion | 2022-02-17 |
| Phase | Phase 2 |
What the finished NCT04830397 record still lists
NCT04830397 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 277-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (70% lower).
The record links to 2 conditions, with Ocular Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Timolol Maleate is the first listed.
NCT04830397 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT04830397 about?
NCT04830397 is a clinical study titled "Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).". Evaluating the safety and tolerability of QLS-101 versus timolol maleate ophthalmic solution in glaucoma or ocular hypertension.
What is the current status of trial NCT04830397?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2021-03-31. Estimated completion is 2022-02-17.
What conditions does trial NCT04830397 study?
This clinical trial studies the following conditions: Ocular Hypertension, Primary Open Angle Glaucoma.
What interventions are being tested in trial NCT04830397?
The interventions under investigation include: Timolol Maleate (DRUG), QLS-101 (DRUG).
Who is sponsoring clinical trial NCT04830397?
This trial is sponsored by Qlaris Bio, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04830397 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04830397's enrollment target sits among peer trials
84 37th of 54 higher than 18 of 54 other Ocular Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ocular Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension
RECRUITING · Phase 2
-
Travoprost Five Day Posology Study
COMPLETED · Phase 2
-
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
COMPLETED · Phase 2
-
Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma
COMPLETED · Phase 2
-
A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension
COMPLETED · Phase 2
-
Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI